Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1701666

Cover Image

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1701666

Laboratory Developed Test Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

PUBLISHED:
PAGES: 319 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
PDF & Excel (Multi User License)
USD 7295
PDF & Excel (Corporate User License)
USD 8495

Add to Cart

Persistence Market Research has recently released a comprehensive report on the global Laboratory Developed Test (LDT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Laboratory Developed Test Market Size (2025E): US$ 9.0 Bn
  • Projected Market Value (2032F): US$ 13.9 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.4%

Laboratory Developed Test Market - Report Scope:

The Laboratory Developed Test (LDT) market encompasses diagnostic tests that are designed, manufactured, and used within a single laboratory. These tests are particularly vital when no commercially available alternatives exist, providing solutions tailored for unique patient populations or emerging health threats. LDTs are widely used in specialized diagnostic areas such as oncology, genetics, infectious diseases, and rare disorders. The increasing demand for personalized medicine, rising prevalence of chronic and infectious diseases, and technological advancements in molecular diagnostics are key contributors to market growth.

Market Growth Drivers:

Several key factors are fueling the growth of the global Laboratory Developed Test market. The rapid rise in personalized medicine and the need for customized diagnostic solutions are encouraging the use of LDTs. Technological advancements, especially in molecular diagnostics and next-generation sequencing, have significantly improved the speed, accuracy, and reliability of these tests. Moreover, the growing burden of cancer, genetic disorders, and infectious diseases globally has amplified the demand for specialized and flexible diagnostic options. The COVID-19 pandemic further highlighted the importance of rapid and adaptable diagnostic tools, driving both awareness and regulatory support for LDTs. Increasing investments in diagnostic research and the growing role of academic and research institutions in developing novel assays also propel the market forward.

Market Restraints:

Despite their advantages, the Laboratory Developed Test market faces several challenges. A key concern is the lack of uniform regulatory oversight across regions, which can lead to variability in test quality and patient safety. The upcoming regulatory changes, particularly in the United States under the proposed VALID Act, could impose stricter compliance burdens on labs, increasing operational costs and limiting innovation. In addition, LDTs often require significant expertise and infrastructure, restricting their widespread use, especially in low-resource settings. Concerns around reproducibility, validation, and standardization further hinder broader adoption. Lastly, competition from FDA-approved commercial tests can reduce the market share for LDTs in certain applications.

Market Opportunities:

The LDT market offers substantial growth opportunities driven by continued innovation in diagnostics and the expanding scope of precision medicine. The increasing integration of artificial intelligence and bioinformatics into laboratory testing presents new possibilities for more accurate and efficient test development. Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing improved healthcare infrastructure and diagnostic capabilities, opening up new avenues for LDT adoption. Moreover, as demand grows for early disease detection and targeted therapies, LDTs are well-positioned to play a central role in niche diagnostic areas such as rare diseases and pharmacogenomics. Partnerships between academic research centers and commercial diagnostic companies can also accelerate LDT development and market reach.

Key Questions Answered in the Report:

  • What are the primary factors driving the global Laboratory Developed Test market's growth?
  • Which regions and application areas are experiencing the highest demand for LDTs?
  • How are technological innovations in molecular diagnostics shaping the LDT landscape?
  • Who are the key players in the Laboratory Developed Test market, and what strategies are they adopting to remain competitive?
  • What are the regulatory developments and future projections for the global LDT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Laboratory Developed Test market, such as Thermo Fisher Scientific Inc., QIAGEN, Roche Diagnostics, and Quest Diagnostics, are focusing on expanding their test portfolios, particularly in oncology, infectious diseases, and genetic testing. These companies are leveraging strategic collaborations with academic institutions, biotech firms, and healthcare providers to enhance innovation and accelerate time-to-market for novel assays. Investment in automation, AI-based data analysis tools, and next-generation sequencing technologies is enabling improved test accuracy and throughput. Furthermore, companies are engaging with regulatory bodies to ensure compliance and support smoother transitions under evolving LDT regulations.

Companies Covered in This Report:

  • Thermo Fisher Scientific Inc.
  • Kaneka Eurogentec S.A.
  • QIAGEN
  • Vastian
  • Roche Diagnostics
  • Adaptive Biotechnologies
  • Guardant Health, Inc.
  • Smiths Medical
  • Quest Diagnostics
  • Beckman Coulter
  • OPKO Health, Inc.

Laboratory Developed Test Market Segmentation:

By Test Type:

  • Clinical Biochemistry
  • Haematology
  • Immunology
  • Microbiology
  • Molecular Diagnostics
  • Others

By Application:

  • Oncology
  • Genetics
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

By End User:

  • Hospital Laboratories
  • Specialty Diagnostics Centers
  • Clinical Research Organizations
  • Research Institutes
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa
Product Code: PMRREP3430

Table of Contents

1. Executive Summary

  • 1.1. Global Laboratory Developed Test Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Reimbursement Scenario
  • 3.4. PESTLE Analysis
  • 3.5. Promotional Strategies, By Key Players

4. Global Laboratory Developed Test Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Laboratory Developed Test Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
      • 4.3.3.1. Clinical Biochemistry
      • 4.3.3.2. Hematology
      • 4.3.3.3. Immunology
      • 4.3.3.4. Microbiology
      • 4.3.3.5. Molecular Diagnostics
      • 4.3.3.6. Others
    • 4.3.4. Market Attractiveness Analysis: Test Type
  • 4.4. Global Laboratory Developed Test Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn), By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Oncology
      • 4.4.3.2. Genetics
      • 4.4.3.3. Infectious Diseases
      • 4.4.3.4. Autoimmune Disorders
      • 4.4.3.5. Other Conditions
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Laboratory Developed Test Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn), By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospital Laboratories
      • 4.5.3.2. Specialty Diagnostics Centers
      • 4.5.3.3. Clinical Research Organizations
      • 4.5.3.4. Research Institutes
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Laboratory Developed Test Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Laboratory Developed Test Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 6.4.1. Clinical Biochemistry
    • 6.4.2. Hematology
    • 6.4.3. Immunology
    • 6.4.4. Microbiology
    • 6.4.5. Molecular Diagnostics
    • 6.4.6. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Oncology
    • 6.5.2. Genetics
    • 6.5.3. Infectious Diseases
    • 6.5.4. Autoimmune Disorders
    • 6.5.5. Other Conditions
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospital Laboratories
    • 6.6.2. Specialty Diagnostics Centers
    • 6.6.3. Clinical Research Organizations
    • 6.6.4. Research Institutes
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Laboratory Developed Test Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 7.4.1. Clinical Biochemistry
    • 7.4.2. Hematology
    • 7.4.3. Immunology
    • 7.4.4. Microbiology
    • 7.4.5. Molecular Diagnostics
    • 7.4.6. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Oncology
    • 7.5.2. Genetics
    • 7.5.3. Infectious Diseases
    • 7.5.4. Autoimmune Disorders
    • 7.5.5. Other Conditions
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospital Laboratories
    • 7.6.2. Specialty Diagnostics Centers
    • 7.6.3. Clinical Research Organizations
    • 7.6.4. Research Institutes
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Laboratory Developed Test Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 8.4.1. Clinical Biochemistry
    • 8.4.2. Hematology
    • 8.4.3. Immunology
    • 8.4.4. Microbiology
    • 8.4.5. Molecular Diagnostics
    • 8.4.6. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Oncology
    • 8.5.2. Genetics
    • 8.5.3. Infectious Diseases
    • 8.5.4. Autoimmune Disorders
    • 8.5.5. Other Conditions
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospital Laboratories
    • 8.6.2. Specialty Diagnostics Centers
    • 8.6.3. Clinical Research Organizations
    • 8.6.4. Research Institutes
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Laboratory Developed Test Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 9.4.1. Clinical Biochemistry
    • 9.4.2. Hematology
    • 9.4.3. Immunology
    • 9.4.4. Microbiology
    • 9.4.5. Molecular Diagnostics
    • 9.4.6. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Oncology
    • 9.5.2. Genetics
    • 9.5.3. Infectious Diseases
    • 9.5.4. Autoimmune Disorders
    • 9.5.5. Other Conditions
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospital Laboratories
    • 9.6.2. Specialty Diagnostics Centers
    • 9.6.3. Clinical Research Organizations
    • 9.6.4. Research Institutes
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Laboratory Developed Test Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 10.4.1. Clinical Biochemistry
    • 10.4.2. Hematology
    • 10.4.3. Immunology
    • 10.4.4. Microbiology
    • 10.4.5. Molecular Diagnostics
    • 10.4.6. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Oncology
    • 10.5.2. Genetics
    • 10.5.3. Infectious Diseases
    • 10.5.4. Autoimmune Disorders
    • 10.5.5. Other Conditions
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospital Laboratories
    • 10.6.2. Specialty Diagnostics Centers
    • 10.6.3. Clinical Research Organizations
    • 10.6.4. Research Institutes
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Laboratory Developed Test Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 11.4.1. Clinical Biochemistry
    • 11.4.2. Hematology
    • 11.4.3. Immunology
    • 11.4.4. Microbiology
    • 11.4.5. Molecular Diagnostics
    • 11.4.6. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Oncology
    • 11.5.2. Genetics
    • 11.5.3. Infectious Diseases
    • 11.5.4. Autoimmune Disorders
    • 11.5.5. Other Conditions
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospital Laboratories
    • 11.6.2. Specialty Diagnostics Centers
    • 11.6.3. Clinical Research Organizations
    • 11.6.4. Research Institutes
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Test Types
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Thermo Fisher Scientific Inc.
      • 12.3.2.1. Overview
      • 12.3.2.2. Segments and Test Types
      • 12.3.2.3. Key Financials
      • 12.3.2.4. Market Developments
      • 12.3.2.5. Market Strategy
    • 12.3.3. Kaneka Eurogentec S.A.
      • 12.3.3.1. Overview
      • 12.3.3.2. Segments and Test Types
      • 12.3.3.3. Key Financials
      • 12.3.3.4. Market Developments
      • 12.3.3.5. Market Strategy
    • 12.3.4. Vastian
      • 12.3.4.1. Overview
      • 12.3.4.2. Segments and Test Types
      • 12.3.4.3. Key Financials
      • 12.3.4.4. Market Developments
      • 12.3.4.5. Market Strategy
    • 12.3.5. Roche Diagnostics
      • 12.3.5.1. Overview
      • 12.3.5.2. Segments and Test Types
      • 12.3.5.3. Key Financials
      • 12.3.5.4. Market Developments
      • 12.3.5.5. Market Strategy
    • 12.3.6. Adaptive Biotechnologies.
      • 12.3.6.1. Overview
      • 12.3.6.2. Segments and Test Types
      • 12.3.6.3. Key Financials
      • 12.3.6.4. Market Developments
      • 12.3.6.5. Market Strategy
    • 12.3.7. Guardant Health, Inc.
      • 12.3.7.1. Overview
      • 12.3.7.2. Segments and Test Types
      • 12.3.7.3. Key Financials
      • 12.3.7.4. Market Developments
      • 12.3.7.5. Market Strategy
    • 12.3.8. Smiths Medical
      • 12.3.8.1. Overview
      • 12.3.8.2. Segments and Test Types
      • 12.3.8.3. Key Financials
      • 12.3.8.4. Market Developments
      • 12.3.8.5. Market Strategy
    • 12.3.9. Quest Diagnostics
      • 12.3.9.1. Overview
      • 12.3.9.2. Segments and Test Types
      • 12.3.9.3. Key Financials
      • 12.3.9.4. Market Developments
      • 12.3.9.5. Market Strategy
    • 12.3.10. Beckman Coulter
      • 12.3.10.1. Overview
      • 12.3.10.2. Segments and Test Types
      • 12.3.10.3. Key Financials
      • 12.3.10.4. Market Developments
      • 12.3.10.5. Market Strategy
    • 12.3.11. OPKO Health, Inc.
      • 12.3.11.1. Overview
      • 12.3.11.2. Segments and Test Types
      • 12.3.11.3. Key Financials
      • 12.3.11.4. Market Developments
      • 12.3.11.5. Market Strategy
    • 12.3.12. Siemens Medical Solutions USA, Inc.
      • 12.3.12.1. Overview
      • 12.3.12.2. Segments and Test Types
      • 12.3.12.3. Key Financials
      • 12.3.12.4. Market Developments
      • 12.3.12.5. Market Strategy
    • 12.3.13. Quanterix
      • 12.3.13.1. Overview
      • 12.3.13.2. Segments and Test Types
      • 12.3.13.3. Key Financials
      • 12.3.13.4. Market Developments
      • 12.3.13.5. Market Strategy
    • 12.3.14. Proteomics International
      • 12.3.14.1. Overview
      • 12.3.14.2. Segments and Test Types
      • 12.3.14.3. Key Financials
      • 12.3.14.4. Market Developments
      • 12.3.14.5. Market Strategy

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!